GLT-1 transporter: An effective pharmacological target for various neurological disorders

Pharmacology Biochemistry and Behavior

Volumn 127, Issue , 2014, Pages 70-81

  Soni, Neha ^a   Reddy, B V K ^a   Kumar, Puneet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Excitotoxicity; GLT 1; Glutamate; Neurological disorders

Indexed keywords

CEFTRIAXONE; ESTRADIOL; GLUTAMATE TRANSPORTER; GROUP III METABOTROPIC RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; RECOMBINANT EPIDERMAL GROWTH FACTOR; TAMOXIFEN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; SLC1A2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DRUG TARGETING; EPILEPSY; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOSIS; REVIEW; AGONISTS; ANIMALS; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEMS; DRUG EFFECTS; HUMANS; METABOLISM; METHODS; NERVOUS SYSTEM DISEASES; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; GLUTAMIC ACID; HUMANS; NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION;

EID: 84910631288     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2014.10.001     Document Type: Article

References (159)

1. Abulseoud OA, Camsari UM, Ruby CL, Kasasbeh A, Choi S, Choi DS. Attenuation of ethanol withdrawal by ceftriaxone-induced upregulation of glutamate transporter EAAT2. Neuropsychopharmacology 2014. http://dx.doi.org/10.1038/npp.2014.14.
2. Aidt FH, Nielsen SM, Kanters J, Pesta D, Nielsen TT, Norremolle A, et al. Dysfunctional mitochondrial respiration in the striatum of the Huntington's disease transgenic R6/2 mouse model. PLoS Curr 2013;5. [PMCID: 3614423].
3. Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. J Neural Transm 2014;121(8):849-59.
4. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000;32(1):1-14.
5. Annweiler C, Brugg B, Peyrin JM, Bartha R, Beauchet O. Combination of memantine and vitamin D prevents axon degeneration induced by amyloid-beta and glutamate. Neurobiol Aging 2014;35(2):331-5.
6. Arnth-Jensen N, Jabaudon D, Scanziani M. Cooperation between independent hippocampal synapses is controlled by glutamate uptake. Nat Neurosci 2002;5(4):325-31.
7. Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A 1997;94(8):4155-60. [PMCID: 20584].
8. Arzberger T, Krampfl K, Leimgruber S, Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT-1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 1997;56(4):440-54. [Apr].
9. Assous M, Had-Aissouni L, Gubellini P, Melon C, Nafia I, Salin P, Kerkerian-Le-Goff L, Kachidian P. Progressive Parkinsonism by acute dysfunction of excitatory amino acid transporters in the rat substantia nigra. Neurobiol Dis 2014;65:69-81.
10. Attwell D, Barbour B, Szatkowski M. Nonvesicular release of neurotransmitter. Neuron 1993;11(3):401-7.
11. Bamford NS, Robinson S, Palmiter RD, Joyce JA,Moore C, Meshul CK. Dopamine modulates release from corticostriatal terminals. J Neurosci 2004;24(43):9541-52.
12. Banerjee S, Williamson D, Habib N, Gordon M, Chataway J. Human stem cell therapy in ischaemic stroke: a review. Age Ageing 2011;40(1):7-13.
13. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003;361(9369):1642-4.
14. Bendotti C, Tortarolo M, Suchak SK, Calvaresi N, Carvelli L, Bastone A, et al. Transgenic SOD1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 2001;79(4):737-46.
15. Bidmon HJ, Görg B, Palomero-Gallagher N, Schleicher A, Häussinger D, Speckmann EJ, Zilles K. Glutamine synthetase becomes nitrated and its activity is reduced during repetitive seizure activity in the pentylentetrazole model of epilepsy. Epilepsia 2008;49(10):1733-48.
16. Blakely RD, Edwards RH. Vesicular and plasma membrane transporters for neurotransmitters. Cold Spring Harb Perspect Biol 2012;4(2). [PMCID: 3281572].
17. Bragina L, Melone M, Fattorini G, Torres-Ramos M, Vallejo-Illarramendi A, Matute C, et al. GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation. J Neurochem 2006;99(1):134-41.
18. Bridges RJ, Esslinger CS. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 2005;107(3):271-85.
19. Bristol LA, Rothstein JD. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 1996;39(5):676-9.
20. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal 2006;8(11-12):2061-73.
21. Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997;18(2):327-38.
22. Carbone M, Duty S, Rattray M. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation. BMC Neurosci 2012;13:38.
23. Chao XD, Fei F, Fei Z. The role of excitatory amino acid transporters in cerebral ischemia. Neurochem Res 2010;35(8):1224-30.
24. Chen NH, Reith ME, Quick MW. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 2004;447(5):519-31.
25. Chen W, Mahadomrongkul V, Berger UV, Bassan M, DeSilva T, Tanaka K, et al. The glutamate transporter GLT-1a is expressed in excitatory axon terminals of mature hippocampal neurons. J Neurosci 2004;24(5):1136-48. [PMCID: 2849838].
26. Chen JC, Hsu-Chou H, Lu JL, Chiang YC, Huang HM, Wang HL, et al. Down-regulation of the glial glutamate transporter GLT-1 in rat hippocampus and striatum and its modulation by a group III metabotropic glutamate receptor antagonist following transient global forebrain ischemia. Neuropharmacology 2005;49(5):703-14.
27. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1(8):623-34.
28. Chotibut T, Davis RW, Arnold JC, Frenchek Z, Gurwara S, Bondada V, et al. Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model. Mol Neurobiol 2013;49(3):1282-92.
29. Chu K, Lee ST, Sinn DI, Ko SY, Kim EH, Kim JM, et al. Pharmacological induction of ischemic tolerance by glutamate transporter-1 (EAAT2) upregulation. Stroke 2007;38(1):177-82.
30. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2(11):806-19.
31. Coulter DA, Eid T. Astrocytic regulation of glutamate homeostasis in epilepsy. Glia 2012;60(8):1215-26. [PMCID: 3375386].
32. Damiano M, Galvan L, Deglon N, Brouillet E. Mitochondria in Huntington's disease. Biochim Biophys Acta 2010;1802(1):52-61.
33. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65(1):1-105.
34. de Almeida RN, Agra Mde F, Maior FN, de Sousa DP. Essential oils and their constituents: anticonvulsant activity. Molecules 2011;16(3):2726-42.
35. de Vivo L, Melone M, Bucci G, Rothstein JD, Conti F. Quantitative analysis of EAAT4 promoter activity in neurons and astrocytes of mouse somatic sensory cortex. Neurosci Lett 2010;474:42-510.
36. Dehnes Y, Chaudhry FA, Ullensvang K, Lehre KP, Storm-Mathisen J, Danbolt NC. The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J Neurosci 1998;18:3606-19.
37. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002;175(2):303-17.
38. Di Cairano ES, Davalli AM, Perego L, Sala S, Sacchi VF, La Rosa S, et al. The glial glutamate transporter 1 (GLT-1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem 2011;286(16):14007-18. [PMCID: 3077601].
39. Divito CB, Underhill SM. Excitatory amino acid transporters: roles in glutamatergic neurotransmission. Neurochem Int 2014;73:172-80.
40. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008;371(9624):1612-23.
41. Dunlop J, Marquis K. Glutamate transport inhibitors as targets for treating psychosis. Drug Discov Today Ther Strateg 2006;3(4):533-7.
42. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004;101(34):12604-9. [PMCID: 515104].
43. Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol Dis 2009;34(1):78-86.
44. Eulenburg V, Gomeza J. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Res Rev 2010;63(1-2):103-12.
45. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet 2010;19(15):3053-67. http://dx.doi.org/10.1093/hmg/ddq212. Epub 2010 May 21. [Aug 1].
46. Farooqui Akhlaq A, Ong Wei-Yi, Horrocks Lloyd A. Glutamate transporters and their role in brain. Neurochemical aspects of excitotoxicity; 2008. p. 51-74.
47. Feng D, Wang W, Dong Y, Wu L, Huang J, Ma Y, et al. Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the PI3K/Akt/NF-κ B signaling pathway. Neuroscience 2014;268:21-32. http://dx.doi.org/10.1016/j.neuroscience.2014.02.053. [Epub 2014 Mar 12].
48. Genda EN, Jackson JG, Sheldon AL, Locke SF, Greco TM, O'Donnell JC, et al. Co-compartmentalization of the astroglial glutamate transporter, GLT-1, with glycolytic enzymes and mitochondria. J Neurosci 2011;31(50):18275-88. [PMCID: 3259858].
49. Gether U, Andersen PH, Larsson OM, Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 2006;27(7):375-83.
50. Ghosh M, Yang Y, Rothstein JD, Robinson MB. Nuclear factor-κB contributes to neurondependent induction of glutamate transporter-1 expression in astrocytes. J Neurosci 2011;31(25):9159-69.
51. Grewer C, Watzke N, Wiessner M, Rauen T. Glutamate translocation of the neuronal glutamate transporter EAAC1 occurs within milliseconds. Proc Natl Acad Sci U S A 2000;97(17):9706-11. [PMCID: 16929].
52. Grewer C, Gameiro A, Zhang Z, Tao Z, Braams S, Rauen T. Glutamate forward and reverse transport: from molecular mechanism to transporter-mediated release after ischemia. IUBMB Life 2008;60(9):609-19. [PMCID: 2632779].
53. Grewer C, Gameiro A, Rauen T. SLC1 glutamate transporters. Pflugers Arch 2014;466(1):3-24. [PMCID: 3896240].
54. Guo H, Lai L, Butchbach ME, Stockinger MP, Shan X, Bishop GA, et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 2003;12:2519-32.
55. Hammer J, Alvestad S, Osen KK, Skare O, Sonnewald U, Ottersen OP. Expression of glutamine synthetase and glutamate dehydrogenase in the latent phase and chronic phase in the kainate model of temporal lobe epilepsy. Glia 2008;56(8):856-68.
56. Harvey BK, Airavaara M, Hinzman J, Wires EM, Chiocco MJ, Howard DB, et al. Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS One 2011;6(8):e22135. [PMCID: 3154194].
57. Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutle NJ, Mylonakou MN, et al. The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS. J Neurosci 2012;32:6000-13.
58. Hughes JR. Absence seizures: a review of recent reports with new concepts. Epilepsy Behav 2009;15(4):404-12.
59. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45(5):583-95.
60. Julien JP. Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 2001;104(4):581-91.
61. Kaila K, Ruusuvuori E, Seja P, Voipio J, Puskarjov M. GABA actions and ionic plasticity in epilepsy. Curr Opin Neurobiol 2013;26C:34-41.
62. Kanai Y, Hediger MA. The glutamate and neutral amino acid transporter family: physiological and pharmacological implications. Eur J Pharmacol 2003;479(1-3):237-47.
63. Kanai Y, Clemencon B, Simonin A, Leuenberger M, Lochner M, Weisstanner M, et al. The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med 2013;34(2-3):108-20.
64. Karaman I, Kizilay-Ozfidan G, Karadag CH, Ulugol A. Lack of effect of ceftriaxone, a GLT-1 transporter activator, on spatial memory in mice. Pharmacol Biochem Behav 2013;108:61-5.
65. Karki P, Webb A, Smith K, Lee K, Son DS, Aschner M, et al. cAMP response element-binding protein (CREB) and nuclear factor κB mediate the tamoxifen-induced upregulation of glutamate transporter 1 (GLT-1) in rat astrocytes. J Biol Chem 2013;288(40):28975-86. [Oct 4].
66. Karki P, Smith K, Johnson Jr J, Lee E. Astrocyte-derived growth factors and estrogen neuroprotection: role of transforming growth factor-α in estrogen-induced upregulation of glutamate transporters in astrocytes. Mol Cell Endocrinol 2014;389(1-2):58-64.
67. Kelsey JE, Neville C. The effects of the beta-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease. Psychopharmacology (Berl) 2014;231(12):2405-15.
68. Kirschner MA, Copeland NG, Gilbert DJ, Jenkins NA, Amara SG. Mouse excitatory amino acid transporter EAAT2: isolation, characterization, and proximity to neuroexcitability loci on mouse chromosome 2. Genomics 1994;24(2):218-24.
69. Kleteckova L, Tsenov G, Kubova H, Stuchlik A, Vales K. Neuroprotective effect of the 3alpha5beta-pregnanolone glutamate treatment in the model of focal cerebral ischemia in immature rats. Neurosci Lett 2014;564C:11-5.
70. Kong Q, Takahashi K, Schulte D, Stouffer N, Lin Y, Lin CL. Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus. Neurobiol Dis 2012;47(2):145-54. [PMCID: 3572547].
71. Koomhin P, Tilokskulchai K, Tapechum S. Ceftriaxone improves spatial learning and memory in chronic cerebral hypoperfused rats. Sci Asia 2012;38:356-63.
72. Koutroumanidou E, Kimbaris A, Kortsaris A, Bezirtzoglou E, Polissiou M, Charalabopoulos K, et al. Increased seizure latency and decreased severity of pentylenetetrazol-induced seizures in mice after essential oil administration. Epilepsy Res Treat 2013;2013:532657. [PMCID: 3684096].
73. Krishnan SN, Desai T, Wyman RJ, Haddad GG. Cloning of a glutamate transporter from human brain. Soc Neurosci 1993;19:219. [Abstr.].
74. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J Neurochem 2001;78(2):413-6. [Jul].
75. Lee SG, Su ZZ, Emdad L, Gupta P, Sarkar D, Borjabad A, et al. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J Biol Chem 2008;283(19):13116-23. http://dx.doi.org/10.1074/jbc.M707697200.
76. Lee E, Sidoryk-Wegrzynowicz M,Wang N, Webb A, Son DS, Lee K, et al. GPR30 regulates glutamate transporter GLT-1 expression in rat primary astrocytes. J Biol Chem 2012a;287(32):26817-28. [PMCID: 3411019].
77. Lee E, Sidoryk-Wegrzynowicz M, Yin Z,Webb A, Son DS, Aschner M. Transforming growth factor-alpha mediates estrogen-induced upregulation of glutamate transporter GLT-1 in rat primary astrocytes. Glia 2012b;60(7):1024-36. [PMCID: 3353324].
78. Lee E, Sidoryk-Wegrzynowicz M, Farina M, Rocha JB, Aschner M. Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes. Neurotox Res 2013;23(2):124-30. [PMCID: 3681521].
79. Lehre K, Danbolt N. The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quanti fication in young adult rat brain. J Neurosci 1998;18:8751-7.
80. Liang Z, Valla J, Sefidvash-Hockley S, Rogers J, Li R. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived fromcortex of Alzheimer's disease patients. J Neurochem 2002;80(5):807-14.
81. Liang SL, Carlson GC, Coulter DA. Dynamic regulation of synaptic GABA release by the glutamate-glutamine cycle in hippocampal area CA1. J Neurosci 2006;26(33):8537-48. [PMCID: 2471868].
82. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160(8):1396-404.
83. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23.
84. Lim G, Wang S, Mao J. cAMP and protein kinase A contribute to the downregulation of spinal glutamate transporters after chronic morphine. Neurosci Lett 2005;376(1):9-13.
85. Lin Y, Roman K, Foust KD, Kaspar BK, Bailey MT, Stephens RL. Glutamate transporter GLT-1 upregulation attenuates visceral nociception and hyperalgesia via spinal mechanisms not related to anti-inflammatory or probiotic effects. Pain Res Treat 2011;2011:507029. [PMCID: 3246297].
86. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4(5):399-415.
87. Lopes MW, Soares FM, de Mello N, Nunes JC, Cajado AG, de Brito D, et al. Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and cerebral cortex in a pilocarpine model of epilepsy. Exp Brain Res 2013;226(2):153-63.
88. Lu Z, Zhang W, Zhang N, Jiang J, Luo Q, Qiu Y. The expression of glutamate transporters in chest compression-induced audiogenic epilepsy: a comparative study. Neurol Res 2008;30(9):915-9.
89. Massie A, Goursaud S, Schallier A, Vermoesen K, Meshul CK, Hermans E, et al. Time-dependent changes in GLT-1 functioning in striatum of hemi-Parkinson rats. Neurochem Int 2010;57(5):572-8.
90. Matos-Ocasio F, Hernández-López A, Thompson KJ. Ceftriaxone, a GLT-1 transporter activator, disrupts hippocampal learning in rats. Pharmacol Biochem Behav 2014;122C:118-21. http://dx.doi.org/10.1016/j.pbb.2014.03.011.
91. Matsugami TR, Tanemura K, Mieda M, Nakatomi R, Yamada K, Kondo T, et al. From the cover: indispensability of the glutamate transporters GLAST and GLT-1 to brain development. Proc Natl Acad Sci U S A 2006;103(32):12161-6. [PMCID: 1524927].
92. Mattson MP. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 2003;3(2):65-94.
93. Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 2013;698(1-3):6-18.
94. Michele B, Fiorenzo C. The mGluR2/3 agonist LY379268 blocks the effects of GLT-1 upregulation on prepulse inhibition of the startle re flex in adult rats. Neuropsychopharmacology 2010;35(6):1253-60. [May].
95. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, et al. Up-regulation of GLT-1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008;153(1):329-37. [PMCID: 2424273].
96. Miller BR, Dorner JL, Bunner KD,Gaither TW, Klein EL, Barton SJ, et al. Up-regulation of GLT-1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease. J Neurochem 2012;121(4):629-38. [PMCID: 3325322].
97. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10(1):79-104.
98. Mogoanta L, Ciurea M, Pirici I, Margaritescu C, Simionescu C, Ion DA, et al. Different dynamics of aquaporin 4 and glutamate transporter 1 distribution in the perineuronal and perivascular compartments during ischemic stroke. Brain Pathol 2014. http://dx.doi.org/10.1111/bpa.12134.
99. Mookherjee P, Green PS,Watson GS, Marques MA, Tanaka K, Meeker KD, et al. GLT-1 loss accelerates cognitive deficit onset in an Alzheimer's disease animal model. J Alzheimers Dis 2011;26(3):447-55. [PMCID: 3256092].
100. Nakagawa T, Kaneko S. SLC1 glutamate transporters and diseases: psychiatric diseases and pathological pain. Curr Mol Pharmacol 2013;6(2):66-73.
101. Nie H, Zhang H, Weng HR. Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. Neuroscience 2010;170(3):901-12. [PMCID: 2939184].
102. Nishizawa Y. Glutamate release and neuronal damage in ischemia. Life Sci 2001;69(4):369-81.
103. Oster S, Radad K, Scheller D, Hesse M, Balanzew W, Reichmann H. Gille G4.Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol 2014;724:31-42.
104. Patel SA, Warren BA, Rhoderick JF, Bridges RJ. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology 2004;46(2):273-84.
105. Pawlak J, Brito V, Kuppers E, Beyer C. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 2005;138(1):1-7.
106. Perego C, Vanoni C, Bossi M, Massari S, Basudev H, Longhi R, et al. The GLT-1 and GLAST glutamate transporters are expressed on morphologically distinct astrocytes and regulated by neuronal activity in primary hippocampal cocultures. J Neurochem 2000;75(3):1076-84.
107. Petr GT, Schultheis LA, Hussey KC, Sun Y, Dubinsky JM, Aoki C, et al. Decreased expression of GLT-1 in the R6/2 model of Huntington's disease does not worsen disease progression. Eur J Neurosci 2013;38(3):2477-90. [PMCID: 3735860].
108. Pines G, Danbolt NC, Bjoras M, Zhang Y, Bendahan A, Eide L, et al. Cloning and expression of a rat brain L-glutamate transporter. Nature 1992;360(6403):464-7.
109. Plaitakis A, Shashidharan P. Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J Neurol 2000;247(Suppl. 2):II25-35.
110. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry 2014;19(1):20-9.
111. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010;17(5):460-6.
112. Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MG, Schrama LH, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2002;125(Pt 1):32-43. [Jan].
113. Rao VL, Bowen KK, Dempsey RJ. Transient focal cerebral ischemia down-regulates glutamate transporters GLT-1 and EAAC1 expression in rat brain. Neurochem Res 2001;26(5):497-502.
114. Rebec GV. Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease. Antioxid Redox Signal 2013;19(17):2115-28. [Dec 10].
115. Ribeiro P, Patocka N. Neurotransmitter transporters in schistosomes: structure, function and prospects for drug discovery. Parasitol Int 2013;62(6):629-38.
116. Robert SM, Ogunrinu-Babarinde T, Holt KT, Sontheimer H. Role of glutamate transporters in redox homeostasis of the brain. Neurochem Int 2014;73:181-91.
117. Robinson MB. The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype. Neurochem Int 1998;33(6):479-91.
118. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44(3):S175-88.
119. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 2000;403(6767):316-21. [Jan 20].
120. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38(1):73-84.
121. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7.
122. Rozyczka J, Figiel M, Engele J. Endothelins negatively regulate glial glutamate transporter expression. Brain Pathol 2004;14(4):406-14.
123. Rusakov DA, Savtchenko LP, Zheng K, Henley JM. Shaping the synaptic signal: molecular mobility inside and outside the cleft. Trends Neurosci 2011;34(7):359-69. [PMCID: 3133640].
124. Salles A, Romano A, Freudenthal R. Synaptic NF-kappa B pathway in neuronal plasticity and memory. J Physiol Paris 2014. http://dx.doi.org/10.1016/j.jphysparis.2014.05.002. [pii: S0928-4257(14)00019-9].
125. Sattler R, Tyler B, Hoover B, Coddington LT, Recinos V, Hwang L, et al. Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma. J Neurosurg 2013;119(4):878-86.
126. Schallier A, Smolders I, Van Dam D, Loyens E, De Deyn PP, Michotte A, et al. Region- and age-speci fic changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J Alzheimers Dis 2011;24(2):287-300.
127. Schmitt A, Asan E, Lesch KP, Kugler P. A splice variant of glutamate transporter GLT-1/EAAT2 expressed in neurons: cloning and localization in rat nervous system. Neuroscience 2002;109(1):45-61.
128. Scimemi A, Meabon JS, Woltjer RL, Sullivan JM, Diamond JS, Cook DG. Amyloid-beta1-42 slows clearance of synaptically released glutamate bymislocalizing astrocytic GLT-1. J Neurosci 2013;33(12):5312-8. [PMCID: 3866500].
129. Scofield MD, Kalivas PW. Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis. Neuroscientist 2014. http://dx.doi.org/10.1177/1073858413520347.
130. Scott HA, Gebhardt FM, Mitrovic AD, Vandenberg RJ, Dodd PR. Glutamate transporter variants reduce glutamate uptake in Alzheimer's disease. Neurobiol Aging 2011;32(3):553. (e1-e11).
131. Seifert G, Steinhauser C. Neuron-astrocyte signaling and epilepsy. Exp Neurol 2013;244:4-10.
132. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298(5594):789-91.
133. Shan D, Yates S, Roberts RC, McCullumsmith RE. Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr 2012;53(3):233-49. [PMCID: 3783347].
134. Shashidharan P, Wittenberg I, Plaitakis A. Molecular cloning of human brain glutamate/aspartate transporter II. Biochim Biophys Acta 1994;1191(2):393-6.
135. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005;171(6):1001-12. [PMCID: 2171327].
136. Sitcheran R, Gupta P, Fisher PB, Baldwin AS. Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J 2005;24(3):510-20.
137. Su ZZ, Leszczyniecka M, Kang DC, Sarkar D, Chao W, Volsky DJ, et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc Natl Acad Sci U S A 2003;100(4):1955-60. [PMCID: 149940].
138. Sun HL, Zhang SH, Zhong K, Xu ZH, Feng B, Yu J, et al. Transient upregulation of glutamine synthetase in the dentate gyrus is involved in epileptogenesis induced by amygdala kindling in the rat. PLoS One 2013;8(6):e66885. [PMCID: 3688959].
139. Swamy M, Yusof WR, Sirajudeen KN, Mustapha Z, Govindasamy C. Decreased glutamine synthetase, increased citrulline-nitric oxide cycle activities, and oxidative stress in different regions of brain in epilepsy rat model. J Physiol Biochem 2011;67(1):105-13.
140. Takai S, Kawakami H, Nakayama T, Yamada K, Nakamura S. Localization of the gene encoding the human L-glutamate transporter (GLT-1) to 11p11.2-p13 by fluorescence in situ hybridization. Hum Genet 1996;97(3):387-9.
141. Takatsuru Y, Nabekura J, Koibuchi N. Contribution of neuronal and glial circuit in intact hemisphere for functional remodeling after focal ischemia. Neurosci Res 2014;78:38-44.
142. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, et al. Epilepsy and exacerbation of brain injury inmice lacking the glutamate transporter GLT-1. Science 1997;276(5319):1699-702.
143. Tsvetkov E, Shin RM, Bolshakov VY. Glutamate uptake determines pathway specificity of long-term potentiation in the neural circuitry of fear conditioning. Neuron 2004;41(1):139-51.
144. 3-induced limbic epilepsy model. Exp Brain Res 2007;181(4):571-7.
145. Utsunomiya-Tate N, Endou H, Kanai Y. Tissue specific variants of glutamate transporter GLT-1. FEBS Lett 1997;416(3):312-6.
146. Vallejo-Illarramendi A, Torres-Ramos M, Melone M, Conti F, Matute C. Clozapine reduces GLT-1 expression and glutamate uptake in astrocyte cultures. Glia 2005;50(3):276-9.
147. van der Hel WS, Notenboom RG, Bos IW, van Rijen PC, van Veelen CW, de Graan PN. Reduced glutamine synthetase in hippocampal areas with neuron loss in temporal lobe epilepsy. Neurology 2005;64(2):326-33.
148. Vandenberg RJ, Ryan RM. Mechanisms of glutamate transport. Physiol Rev 2013;93(4):1621-57.
149. Vanoni C, Massari S, Losa M, Carrega P, Perego C, Conforti L, et al. Increased internalisation and degradation of GLT-1 glial glutamate transporter in a cell model for familial amyotrophic lateral sclerosis (ALS). J Cell Sci 2004;117(Pt 22):5417-26.
150. Varsou O, Macleod MJ, Schwarzbauer C. Functional connectivity magnetic resonance imaging in stroke: an evidence-based clinical review. Int J Stroke 2014;9(2):191-8.
151. Verma R, Mishra V, Sasmal D, Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur J Pharmacol 2010;638(1-3):65-71.
152. Veruki ML, Morkve SH, Hartveit E. Activation of a presynaptic glutamate transporter regulates synaptic transmission through electrical signaling. Nat Neurosci 2006;9:1388-9610. [1038/nn1793].
153. Walker FO. Huntington's disease. Lancet 2007;369(9557):218-28.
154. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008;320(5875):539-43.
155. Woltjer RL, Duerson K, Fullmer JM, Mookherjee P, Ryan AM, Montine TJ, et al. Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease. J Neuropathol Exp Neurol 2010;69(7):667-76. [PMCID: 3097122].
156. Ye ZC, Sontheimer H. Cytokine modulation of glial glutamate uptake: a possible involvement of nitric oxide. Neuroreport 1996;7:2181-5.
157. Yuan Y, Niu F, Liu Y, Lu N. Zinc and its effects on oxidative stress in Alzheimer's disease. Neurol Sci 2014;35(6):923-8.
158. Zelenaia O, Schlag BD, Gochenauer GE, Ganel R, Song W, Beesley JS, et al. Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Mol Pharmacol 2000;57(4):667-78.
159. Zhao Y, Cudkowicz ME, Shefner JM, Krivickas L, David WS, Vriesendorp F, et al. Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J Clin Pharmacol 2014. http://dx.doi.org/10.1002/jcph.317.